Icon-facebook Twitter Linkedin
Contact Us
Contact Us

News and Events

FDA Grants Orphan Drug Designation to LMP744 for Glioma

October 11, 2024
The FDA has granted orphan drug designation to the small molecule, indenoisoquinoline-based topoisomerase I inhibitor LMP744 for the treatment of patients with gliomas...
Keep Reading

FDA grants orphan drug designation to LMP400 for the treatment of glioma

October, 2023
In October 2023, the U.S. Food and Drug Administration (FDA) granted orphan drug status to LMP400 (indotecan) for use in patients with malignant glioma, a cancer of the brain that begins in glial cells (cells that surround and support nerve cells)...
Keep Reading

2024 Topoisomerases in Biology and Medicine Conference

July 15, 2024
Topoisomerases are nuclear enzymes that control the dynamic genome structures in all living organisms, regulating the winding of the DNA double helix and untangling DNA and RNA for cells to carry out the required functions for life.
Keep Reading

Powerful Drug Combination Kills Glioblastoma Tumors Containing a Unique Genetic Makeup

September 19, 2023
Researchers conducted preclinical experiments to explore a treatment that damages brain tumors’ DNA and prevents the cells from repairing it.
Keep Reading

Gibson Oncology Congratulates Dr. Danzhou Yang as Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at Purdue University

April 22, 2021
Dr. Yang, a valued member of Gibson Oncology’s Scientific Advisory Committee, Is also the Martha and Fred Borch Endowed Chair in Cancer Therapeutics at Purdue...
Keep Reading

Gibson Oncology Expands its Scientific Advisory Board for Novel Oncology cMYC Program

May 20, 2020

Summary

Gibson Oncology, LLC (“Gibson”), a privately-held clinical-stage company, has secured worldwide, exclusive commercial rights to a novel series of 56 rationally designed compounds called Azaindenoisoquinolines (“Aza Compounds”), from Purdue University and the National Cancer Institute....
Keep Reading

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

February 19, 2020

Summary

Topoisomerase (TOP) inhibitors are chemotherapeutic drugs that cause DNA double-strand breaks during DNA replication. These can be repaired by homologous recombination, but some tumors, such as triple-negative breast cancer, have defects in proteins needed for this type of repair...
Keep Reading

Gibson Oncology Obtains Exclusive Commercial Rights to Novel Anti-Cancer Drugs That Inhibit the “Undruggable” cMYC Oncogene, a Key Driver for the Majority of Cancers

February 10, 2020
Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the U.S...
Keep Reading

Gibson’s Novel Anti-cancer Drug, LMP400, Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing Sarcoma

December 12, 2018
Topoisomerases are nuclear enzymes that control the dynamic genome structures in all living organisms, regulating the winding of the DNA double helix and untangling DNA and RNA for cells to carry out the required functions for life.
Keep Reading

The National Cancer Institute (NCI) Demonstrates Anti-Cancer Efficacy and Safety of Gibson’s Novel Class of Indenoisoquinolines in Advanced Canine Lymphoma

October 1, 2018
Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, announced today that the National Cancer Institute (NCI) reported study results from an extensive multi-center canine study using Gibson’s Indenoisoquinolines (LMP400, LMP766, and LMP744) to treat 84 dogs with advanced stages of lymphoma...
Keep Reading

Gibson Oncology, LLC Acquires Novel Anti-Cancer Drugs from Linus Oncology

September 6, 2018
Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company, acquired three (3) clinical non-camptothecin Topoisomerase I drugs from Linus Oncology...
Keep Reading

7772 Fisher Drive  Miami, FL 33109

Sign Up!

Stay up to date and get notifications via email when we post updates

Contact Info

Phone: 305-674-7072
Email: info@gibsononcology.com

Copyright © 2024 Gibson Oncology, All rights reserved.